HIV-1 isolates were recovered from biopsy tissues from the small bowel, colon, and rectum of 10 infected individuals with severe diarrhea. In general, the bowel strains grew well in primary macrophage and lymphocyte cultures, not in T or B cell lines. They induced cytopathic effects such as syncytia formation and cell killing in peripheral blood mononuclear cells and were usually sensitive to serum neutralization. Several of these isolates were able to infect bowel epithelial cell lines, but this characteristic was also observed with blood-derived strains. Differences could be identified in 3 of 6 cases of paired bowel and blood isolates from the same individual. When compared to blood-derived isolates, the bowel strains exhibited a relative inability to grow in established cell lines, a reduced ability to induce cytopathology in infected cells, and a greater sensitivity to serum neutralization. Thus, although distinct characteristics of bowel-derived HIV-1 strains were not found, certain biological and serological properties might differentiate these viruses from those isolated from other tissues.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/0042-6822(91)90621-h | DOI Listing |
JCO Glob Oncol
January 2025
Division of Haematology/Oncology, The Hospital for Sick Children, Toronto, Canada.
Purpose: Asparaginase (ASN) is a critical component of pediatric ALL protocols. Until recently, ASN was available in three formulations: native Escherichia coli, PEGylated E. coli (PEG), and Erwinase, with native E.
View Article and Find Full Text PDFProc Natl Acad Sci U S A
February 2025
State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou 510050, China.
Chromobox 2 (CBX2), a crucial component of the polycomb repressive complex (PRC), has been implicated in the development of various human cancers. However, its role in the regulation of tumor immunogenicity and immune evasion remains inadequately understood. In this study, we found that ablation of CBX2 led to tumor growth inhibition, activation of the tumor immune microenvironment, and enhanced therapeutic efficacy of anti-PD1 or adoptive T cell therapies by using murine syngeneic tumor models.
View Article and Find Full Text PDFWe lack tools to edit DNA sequences at scales necessary to study 99% of the human genome that is noncoding. To address this gap, we applied CRISPR prime editing to insert recombination handles into repetitive sequences, up to 1697 per cell line, which enables generating large-scale deletions, inversions, translocations, and circular DNA. Recombinase induction produced more than 100 stochastic megabase-sized rearrangements in each cell.
View Article and Find Full Text PDFPLoS Comput Biol
January 2025
School of Software, Taiyuan University of Technology, Taiyuan, China.
Personalized cancer drug treatment is emerging as a frontier issue in modern medical research. Considering the genomic differences among cancer patients, determining the most effective drug treatment plan is a complex and crucial task. In response to these challenges, this study introduces the Adaptive Sparse Graph Contrastive Learning Network (ASGCL), an innovative approach to unraveling latent interactions in the complex context of cancer cell lines and drugs.
View Article and Find Full Text PDFPLoS One
January 2025
Department of Nutrition, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States of America.
Aflatoxin B1 (AFB1) is a class 1 carcinogen and mycotoxin known to contribute to the development of hepatocellular carcinoma (HCC), growth impairment, altered immune system modulation, and malnutrition. AFB1 is synthesized by Aspergillus flavus and is known to widely contaminate foodstuffs, particularly maize, wheat, and groundnuts. The mechanism in which AFB1 causes genetic mutations has been well studied, however its metabolomic effects remained largely unknown.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!